Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology

Description:

Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Clinical Trial Endpoints in Oncology – Inclusion of Surrogate Endpoints and Shorter Endpoints will Ensure Faster Clinical Trials in Oncology”, which essentially provides insights into clinical trial endpoints in oncology. The report details the endpoints and application of endpoints in oncological clinical trials. The report also analyzes the major four markets which include the colorectal cancer, prostate cancer, head and neck cancer and ovarian cancer therapeutics markets. It includes the analysis of endpoints of the major marketed products and their profiling. In addition to marketed products, the Phase III and Phase II clinical trials are also analyzed in terms of percentage cases. Analysis of prevailing and upcoming trends and their effects on the market and company profiling of major companies are included in the report.

Scope

The report details the endpoints and application of endpoints in Oncology Clinical Trials. The report covers -
- Data and analysis on the marketed products and analysis of endpoints used for the approval of the product.
- Analysis of the four major markets, which includes the colorectal cancer, prostate cancer, head and neck cancer and ovarian cancer therapeutics markets.
- Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Analysis of terminated trials is also included in this chapter. Only industry sponsored studies are included in the report.
- Trend Analysis analyzes prevailing and upcoming trends and their effects on the market.
- Company Profiling talks in detail about the companies which are strong in the market.

Reasons to buy

The report will help business development and marketing executives who are strategizing their product launches to -
- Build an effective R&D strategy by identifying the current state of endpoint achieved by the marketed products
- Identify the disease unmet needs for the four major cancers and align your pipeline product portfolio to tap the market potential.
- Improve our future market position by aligning your R&D pipeline to the areas with maximum success potential
- Improve your R&D efficiency by reducing research expenditure on unsuccessful endpoints
- Develop key strategic initiatives by understanding the key focus of leading companies with strong product pipeline.

Contents:

1
1 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Clinical Trials Endpoints in Oncology – Introduction 7
2.1 Introduction 7
2.2 GBI Research Report Guidance 8
3 Clinical Trials Endpoints in Oncology – Market Overview 9
3.1 Endpoints Used for Regular Approval 9
3.1.1 Survival 11
3.1.2 Progression-free survival 11
3.1.3 Tumor Response, Response Duration, and Time-to-Tumor Progression 12
6.8.3 Major Oncology Products 114
7 Clinical Trials Endpoints In Oncology – Appendix 115
7.1 Market Definitions 115
7.2 Abbreviations 115
7.3 Research Methodology 118
7.3.1 Coverage 118
7.3.2 Secondary Research 118
7.3.3 Primary Research 119
7.3.4 Expert Panel Validation 119
7.4 Contact Us 119
7.5 Disclaimer 120
7.6 Sources 120

1.1 List of Tables
Table 1: Endpoints for Approval of Oncology Drug Marketing Applications, Global, 1990-2010 9
Table 2: Colorectal Cancer Therapeutics Market – Approved Products, Global, 1990-2010 13
Table 3: Colorectal Cancer Therapeutics Market, Global, Efficacy, 2010 14
Table 4: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010 20
Table 5: Colorectal Cancer Therapeutics Market, Phase III Molecules, Global, 2010 25
Table 6: Colorectal Cancer Therapeutics Market, Phase II Molecules, Global, 2010 30
Table 7: Discontinued Drugs for Colorectal Cancer, Global, 2010 35
Table 8: Prostate Cancer Therapeutics Market- Approved Products, Global, 1990-2010 36
Table 9: Prostate Cancer Therapeutics Market, Global, Efficacy, Global, 2010 37
Table 10: Prostate Cancer Therapeutics Market, Phase III Molecules, Global, 2010 55
Table 11: Prostate Cancer Therapeutics Market, Phase II Molecules, Global, 2010 59
Table 12: Discontinued Drugs for Prostate Cancer, Global, 2010 63
Table 13: Head and Neck Cancer Therapeutics Market – Approved Products, Global, 1990-2010 63
Table 14: Head and Neck Cancer Therapeutics Market, Global, Efficacy, 2010 64
Table 15: Head and Neck Cancer Therapeutics Market, Phase III Molecules, Global, 2010 71
Table 16: Head and Neck Cancer Therapeutics Market, Phase II Molecules, Global, 2010 74
Table 17: Discontinued Drugs for Head and Neck Cancer, Global, 2010 76
Table 18: Ovarian Cancer Therapeutics Market- Approved Products, Global, 1990-2010 77
Table 19: Ovarian Cancer Therapeutics Market, Global, Efficacy, 2010 77
Table 20: Ovarian Cancer Therapeutics Market, Phase III Molecules, Global, 2010 87
Table 21: Ovarian Cancer Therapeutics Market, Phase II Molecules, Global, 2010 90
Table 22: Discontinued Drugs for Ovarian Cancer, Global, 2010 93
Table 23: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010 102

1.2 List of Figures
Figure 1: Colorectal Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 22
Figure 2: Colorectal Cancer Therapeutics Market – Clinical Pipeline Phase II by Primary Endpoints, 2010 29
Figure 3: Prostate Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 50
Figure 4: Prostate Cancer Therapeutics Market – Clinical Pipeline Phase II by Primary Endpoints, 2010 58
Figure 5: Head and Neck Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 68
Figure 6: Head and Neck Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 73
Figure 7: Ovarian Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 81
Figure 8: Ovarian Cancer Therapeutics Market – Clinical Pipeline Phase II by Primary Endpoints, 2010 89

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/1587029/](http://www.researchandmarkets.com/reports/1587029/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology |
| Web Address: | http://www.researchandmarkets.com/reports/1587029/ |
| Office Code: | SCD2ST6K |

Product Formats
Please select the product formats and quantity you require:

| Electronic (PDF) - Single User: | USD 3500 |
| Electronic (PDF) - Site License: | USD 7000 |
| Electronic (PDF) - Enterprisewide: | USD 10500 |

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

Title: | Mr | Mrs | Dr | Miss | Ms | Prof |
---|---|---|---|---|---|---|
First Name: | | | | | | |
Last Name: | | | | | | |
Email Address: * | | | | | | |
Job Title: | | | | | | |
Organisation: | | | | | | |
Address: | | | | | | |
City: | | | | | | |
Postal / Zip Code: | | | | | | |
Country: | | | | | | |
Phone Number: | | | | | | |
Fax Number: | | | | | | |

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World